66 related articles for article (PubMed ID: 18386224)
1. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini AM; Pirrelli M; Caruso ML
Curr Opin Mol Ther; 2008 Apr; 10(2):124-31. PubMed ID: 18386224
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
3. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
Loupakis F; Vasile E; Santini D; Masi G; Falcone A; Graziano F
Pharmacogenomics; 2008 Jan; 9(1):55-69. PubMed ID: 18154448
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
[TBL] [Abstract][Full Text] [Related]
6. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
10. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.
Italiano A
Oncology; 2006; 70(3):161-7. PubMed ID: 16675911
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
[TBL] [Abstract][Full Text] [Related]
14. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.
Bhargava R; Chen B; Klimstra DS; Saltz LB; Hedvat C; Tang LH; Gerald W; Teruya-Feldstein J; Paty PB; Qin J; Shia J
Cancer; 2006 Apr; 106(8):1857-62. PubMed ID: 16532444
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
Shia J; Klimstra DS; Li AR; Qin J; Saltz L; Teruya-Feldstein J; Akram M; Chung KY; Yao D; Paty PB; Gerald W; Chen B
Mod Pathol; 2005 Oct; 18(10):1350-6. PubMed ID: 15832190
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?
Saltz L
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S98-100. PubMed ID: 16336755
[TBL] [Abstract][Full Text] [Related]
19. Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab.
Liu J; Zhou Q; Xu J; Wang J; Zhang Y
J BUON; 2016; 21(1):95-100. PubMed ID: 27061536
[TBL] [Abstract][Full Text] [Related]
20. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor.
Dei Tos AP
Int J Biol Markers; 2007; 22(1 Suppl 4):S3-9. PubMed ID: 17520579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]